CM
HRMY icon

Caption Management’s Harmony Biosciences HRMY Stock Holding History

Caption Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-285,000
Closed -$7.85M – 1797
2025
Q3 		$7.85M Buy
+285,000
New +$9.82M 0.06% 349
2023
Q4 		– Sell
-65,000
Closed -$2.13M – 1479
2023
Q3 		$2.13M Buy
+65,000
New +$2.26M 0.03% 560

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caption Management's HRMY Position: Q2 2026 in Review

Caption Management sold out of Harmony Biosciences (HRMY) in Q2 2026, closing a stake of 272,292 shares — an estimated $7.63M sold.

Caption Management first reported a position in HRMY in Q1 2023 and held it in 3 quarters. The position peaked at $7.63M in Q1 2026. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Caption Management reported no remaining Harmony Biosciences position as of Q2 2026 after selling out during the quarter.
  • Caption Management sold 272,292 Harmony Biosciences shares in Q2 2026, an estimated $7.63M.
  • Caption Management first reported a position in Harmony Biosciences in Q1 2023 and held it in 3 quarters.
  • Caption Management's Harmony Biosciences position peaked at $7.63M in Q1 2026.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.